FRESENIUS KABI

URGENT DRUG RECALL

July 16, 2026

Product Name/Product Size	Unit of Use NDC Number	Unit of Sale NDC Number	Product Code	Batch Number	Expiration Date	First Ship Date	Last Ship Date
Glycopyrrolate Injection, USP, 1 mg / 5 mL (0.2 mg / mL), 5 mL fill in a 6.5 mL vial	**63323-578-07**	**63323-578-05**	**578105**	**6134349**	**11/2026**	**07/29/2025**	**01/27/2026**
				6134620	**11/2026**	**12/19/2025**	**12/19/2025**
Lidocaine Hydrochloride Injection, USP, 2% (100 mg / 5 mL) (20 mg / mL), 5 mL fill in a 6 mL vial	**63323-208-01**	**63323-208-05**	**20805**	**6133801**	**01/2028**	**04/03/2025**	**06/18/2025**
Naropin® (ropivacaine HCl Injection, USP), 0.5% (100 mg / 20 mL) (5 mg / mL), 20 mL fill in a 20 mL vial	**63323-286-05**	**63323-286-23**	**278623**	**6133436**	**10/2028**	**05/01/2025**	**07/09/2025**
Xylocaine® (lidocaine HCl Injection, USP), 1% (200 mg / 20 mL) (10 mg / mL), 20 mL fill in a 20 mL vial	**63323-485-01**	**63323-485-27**	**480527**	**6130235**	**02/2027**	**05/10/2023**	**07/24/2023**
Xylocaine® (lidocaine HCl Injection, USP), 1% (500 mg / 50 mL) (10 mg / mL), 50 mL fill in a 50 mL vial	**63323-485-03**	**63323-485-57**	**480557**	**6133986**	**02/2029**	**09/24/2025**	**10/17/2025**

Dear Customer/Healthcare Professional:

This letter is to notify you that Fresenius Kabi USA, LLC ("Fresenius Kabi") is voluntarily recalling the above-mentioned batches of Glycopyrrolate Injection, USP, 1 mg / 5 mL (0.2 mg / mL), 5 mL fill in a 6.5 mL vial, Lidocaine Hydrochloride Injection, USP, 2% (100 mg / 5 mL) (20 mg / mL), 5 mL fill in a 6 mL vial, Naropin® (ropivacaine HCl Injection, USP), 0.5% (100 mg / 20 mL) (5 mg / mL), 20 mL fill in a 20 mL vial, Xylocaine® (lidocaine HCl Injection, USP), 1% (200 mg / 20 mL) (10 mg / mL), 20 mL fill in a 20 mL vial, and Xylocaine® (lidocaine HCl Injection, USP), 1% (500 mg / 50 mL) (10 mg / mL), 50 mL fill in a 50 mL vial.

This recall is being performed to the user level. Fresenius Kabi has decided to take this action for the potential presence of particulate matter. Reference Attachment A for product labeling.

The Health Hazard Evaluation concluded an overall low risk to patients. No adverse event reports have been received for any of the above-listed batches to date.

You are required to **DESTROY** all product from the above-mentioned batch numbers that you have in your possession. To implement this recall, please do the following:

1. Examine your stock **immediately** to determine if you have any product from the affected batches. Quarantine any affected stock. If you are a distributor, immediately notify your customers that have been shipped or may have been shipped this product of this recall and direct them to quarantine and discontinue distributing or dispensing the affected batches. Please have them prepare to **DESTROY** the product. Your notification to your customers may be enhanced by including a copy of this recall notification letter. Your customers may retrieve the recall letter and response form at https://www.fresenius-kabi.com/us/pharmaceutical-product-updates.

2. If you have the affected batches available, **immediately** quarantine and discontinue distributing, dispensing, or using the batches, and **DESTROY** all vials using your current vendor / hauler of non-hazardous regulated medical waste. A credit memo will **NOT** be issued covering the quantity until a letter of destruction is received from you.

3. **PLEASE COMPLETE THE ENCLOSED "URGENT DRUG RECALL RESPONSE FORM" AND SEND IT BACK TO US IMMEDIATELY VIA EMAIL TO FK-NARECALLS@FRESENIUS-KABI.COM OR FAX AT 1-708-649-8630.**

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047

Main: 847-550-2300
Toll Free: 888-391-6300
www.fresenius-kabi.com/us

FRESENIUS KABI

URGENT DRUG RECALL

CONTACT NUMBERS: Use the following contact phone numbers. Hours of operation: Monday through Friday 8:00 am to 5:00 pm CST

Number	Department	Reason to Call
(866) 716-2459	Quality Assurance Department	Information on how to return product
(800) 551-7176	Vigilance or Medical Affairs	For clinical/technical information/Adverse Drug Events (ADE) reporting

This recall is being made with the knowledge of the United States Food and Drug Administration (FDA).

We apologize for any inconvenience this voluntary recall may cause you.

Sincerely,

Anthony Giessert, Ph.D.
Senior Vice President, Quality Assurance
Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047

Main: 847-550-2300
Toll Free: 888-391-6300
www.fresenius-kabi.com/us

URGENT DRUG RECALL

Attachment A
Product Labeling

Glycopyrrolate Injection, USP, batch 6134349:

Glycopyrrolate Injection, USP, batch 6134620:



Lidocaine Hydrochloride Injection, USP, batch 6133801:



Naropin® (ropivacaine HCl Injection, USP), batch 6133436:



Xylocaine® (lidocaine HCl Injection, USP), batch 6130235:

Xylocaine® (lidocaine HCl Injection, USP), batch 6133986:



Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047

Main: 847-550-2300
Toll Free: 888-391-6300
www.fresenius-kabi.com/us

FRESENIUS KABI

URGENT: DRUG RECALL – Sterile Injectable

URGENT DRUG RECALL RESPONSE FORM

JULY 16, 2026

Please complete and fax or email to: 1-708-649-8630 or FK-NARECALLS@FRESENIUS-KABI.COM

To: Fresenius Kabi USA, LLC **Attn:** Quality Assurance Department

Product Name/Product Size	Unit of Use NDC Number	Unit of Sale NDC Number	Product Code	Batch Number	Expiration Date	First Ship Date	Last Ship Date
Glycopyrrolate Injection, USP, 1 mg / 5 mL (0.2 mg / mL), 5 mL fill in a 6.5 mL vial	63323-578-07	63323-578-05	578105	6134349	11/2026	07/29/2025	01/27/2026
				6134620	11/2026	12/19/2025	12/19/2025
Lidocaine Hydrochloride Injection, USP, 2% (100 mg / 5 mL) (20 mg / mL), 5 mL fill in a 6 mL vial	63323-208-01	63323-208-05	20805	6133801	01/2028	04/03/2025	06/18/2025
Naropin® (ropivacaine HCl Injection, USP), 0.5% (100 mg / 20 mL) (5 mg / mL), 20 mL fill in a 20 mL vial	63323-286-05	63323-286-23	278623	6133436	10/2028	05/01/2025	07/09/2025
Xylocaine® (lidocaine HCl Injection, USP), 1% (200 mg / 20 mL) (10 mg / mL), 20 mL fill in a 20 mL vial	63323-485-01	63323-485-27	480527	6130235	02/2027	05/10/2023	07/24/2023
Xylocaine® (lidocaine HCl Injection, USP), 1% (500 mg / 50 mL) (10 mg / mL), 50 mL fill in a 50 mL vial	63323-485-03	63323-485-57	480557	6133986	02/2029	09/24/2025	10/17/2025

1. Examine your inventory **immediately** to determine if you have any product from the above-mentioned batches.

2. If so, **immediately** discontinue distribution or dispensing of the affected batches and **DESTROY** all units using your current vendor / hauler of non-hazardous regulated medical waste. A credit memo will NOT be issued covering the quantity until a letter of destruction is received from you.

3. **PLEASE COMPLETE THIS FORM AND SEND IT BACK TO US IMMEDIATELY VIA EMAIL AT FK-NARECALLS@FRESENIUS-KABI.COM OR FAX AT 1-708-649-8630.**

☐ We currently do not have units of the batch number on hand.

☐ We are **DESTROYING** _____ Vials ☐ We are **DESTROYING** _____ Trays/Cartons

4. I have identified and contacted direct account customers indicated below that have been shipped or may have been shipped this product. They have prepared to **DESTROY** the product.

YES ☐ I do not have direct account customers ☐

FROM: Hospital (other):_____

Street Address:_____

City, State, Zip code: _____

Phone Number: _____

Signature:_____

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047

Main: 847-550-2300
Toll Free: 888-391-6300
www.fresenius-kabi.com/us